



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

5th September 2013

SAFINAMIDE CLINICAL TRIAL RESULTS

European Journal of Neurology [2013] September 11 [Epub ahead of print] (A.H.Schapira, F.Stocchi, R.Borghain, M.Onofrj, M.Bhatt, P.Lorenzana, V.Lucini, R.Giuliani, R.Anand)

Safinamide is believed to have both dopaminergic and non-dopaminergic actions, including the inhibition of MAO-B and inhibition of glutamate release. It is undergoing Phase III clinical development as a once-daily add-on to dopamine agonists for the treatment of early Parkinson's Disease. For more information go to Safinamide :

<http://www.newron.com/ENG/Default.aspx?SEZ=3&PAG=39>

In a one year clinical trial people with Parkinson's Disease received 100mg or 200mg Safinamide daily. They were assessed according to how long it was before they had to increase their dopamine agonist dose or add another Parkinson's Disease treatment. People receiving 100 mg/day safinamide experienced a significantly lower rate of intervention compared with placebo, of 25% instead of 51% and a small delay before the need to increase other Parkinson's Disease treatments of 9 days.

In a previous study of once daily dosages of 50mg to 100mg Safinamide improved Parkinson's Disease symptoms after six months and reduced "off" time when added on to the use of existing Parkinson's Disease treatments. However, the reduction in "off" time in comparison to the use of a placebo was minimal. The increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide. For more information go to : <http://www.ncbi.nlm.nih.gov/pubmed/22967035>

<http://www.viartis.net/parkinsons.disease/news/130905.pdf>
mail@viartis.net

©2013 Viartis